SCHEMBL3004586

SCHEMBL3004586

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GRM5 P41594 1/20 0.35
NPC1 O15118 3/20 0.35
F2 P00734 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
POLB P06746 1/20 0.34
HTR6 P50406 1/20 0.34
MAPT P10636 3/20 0.33
LMNA P02545 3/20 0.33
CTPS1 P17812 2/20 0.33
KDM1A O60341 1/20 0.33
TSHR P16473 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ADAMTS5 Q9UNA0 1/20 0.33
CHRM4 P08173 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007230 0.95 SMN1; SMN2 (0.38) RAB9ASMN1; SMN2NPC1F2F2RL3
SCHEMBL3017652 0.94 RAB9A (0.39) RAB9ASMN1; SMN2GRM5NPC1F2
SCHEMBL3013182 0.92 LMNA (0.37) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL3009991 0.90 LMNA (0.35) RAB9ASMN1; SMN2GRM5NPC1POLB
SCHEMBL3001213 0.90 RAB9A (0.40) RAB9ASMN1; SMN2GRM5NPC1F2
SCHEMBL2998218 0.90 DRD2 (0.37) RAB9ASMN1; SMN2NPC1POLBMAPT
SCHEMBL3013735 0.89 GPR6 (0.39) RAB9ASMN1; SMN2GRM5NPC1MAPT
SCHEMBL3014529 0.89 NPC1 (0.35) RAB9ASMN1; SMN2NPC1POLBMAPT
SCHEMBL3013472 0.89 SMN1; SMN2 (0.38) RAB9ASMN1; SMN2F2F2RL3POLB
SCHEMBL3015080 0.89 RAB9A (0.38) RAB9ASMN1; SMN2NPC1F2F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885GRM5 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.